Evidence Table 5. Studies of the Efficacy of Gingko Biloba in Treatment of Alzheimer's Disease

AuthorN RCTsIntervention OutcomesResult Quality & Comments
PatientsDrugDosePeriodScaleTrxPlaceboP value/ NNT
Oken et al, 1998118 5 RCTsEGB-761120–240 mg/day2–12 weeksCognitiveCognitive function over all effect size0.413(95% CI, 0.22, 0.61)Good
(Systematic review)424 pts2–24 weeksTranslate on ADAS-Cog2.1(95% CI, 1.12, 3.01)Authors conclude that there is a small but significant effect of 3–6 months treatment with 120–240 mg of EGB-761 on objective measures of cognitive in Alzheimer's disease
1–26 weeks
Le Bars et al., 1997106 309 ptsEGB-761120 mg/day6.5 monthsGlobalCGIC over all ITT (mean)4.24.2 P = 0.77Fair (not all outcomes were considered)
13 monthsCognitiveADAS-Cog over all ITT (mean change)+0.1+1.5 P = 0.04AR at 6.5 months = 25%
Physical functionADAS-Cog 6.5 months (mean change)-0.5+2.1 P = 0.04AR at 13 months = 58%
ADAS-Cog 13 months (mean change)-0.3+1.5 P = 0.005GERRI is not an established instrument.
GERRI over all ITT (mean change)-0.06+0.08 P = 0.004Dementia type: Alzheimer's disease
GERRI 6.5 months (mean change)-0.07+0.07 P = 0.04
GERRI 13 months (mean change)-0.09+0.10 P = 0.002

From: Appendix B. Evidence Tables

Cover of Screening for Dementia
Screening for Dementia [Internet].
Systematic Evidence Reviews, No. 20.
Boustani M, Peterson B, Harris R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.